Company intelligence / Profile preview

Incozen Therapeutics

Hyderabad, Telangana, Indiaincozen.com ↗

Ownership: Private
Employees: ~40
Development stage: Phase 3

Overview

Incozen has developed a pipeline of small molecule drug candidates targeting oncology and immunology indications, with several programs reaching preclinical or early clinical stages. Some assets have been discontinued, while others remain in development for conditions such as asthma and hematologic cancers. The company is recognized for its collaborative R&D model and risk-sharing partnerships in drug discovery, particularly within oncology.

Therapeutic areas: PulmonologyOncologyImmunologyHematology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

tenalisib

Phase 3

Indications: Lymphoma

Partnerships

Rhizen Pharma SA, Switzerland

Beyond the preview

Go deeper on Incozen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Incozen Therapeutics.

Explore the full profile